Fonte: Blood advances. Unidade: FM
Assuntos: TRANSPLANTE HOMÓLOGO, LINFÓCITOS T, LEUCEMIA MIELOIDE AGUDA, DOENÇAS DA MEDULA ÓSSEA, DOENÇA ENXERTO-HOSPEDEIRO, FÁRMACOS IMUNOSSUPRESSORES, CONDICIONAMENTO, SOBREVIVÊNCIA LIVRE DE DOENÇA, ESTUDOS RETROSPECTIVOS
ABNT
SOLOMON, Scott R et al. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood advances, v. 3, n. 19, p. 2836-2844, 2019Tradução . . Disponível em: https://doi.org/10.1182/bloodadvances.2019000627. Acesso em: 09 nov. 2024.APA
Solomon, S. R., Martin, A. S., Shah, N. N., Fatobene, G., Malki, M. M. A., Ballen, K. K., et al. (2019). Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood advances, 3( 19), 2836-2844. doi:10.1182/bloodadvances.2019000627NLM
Solomon SR, Martin AS, Shah NN, Fatobene G, Malki MMA, Ballen KK, Bashey A, Bejanyan N, Meade JB, Rocha V. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy [Internet]. Blood advances. 2019 ; 3( 19): 2836-2844.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1182/bloodadvances.2019000627Vancouver
Solomon SR, Martin AS, Shah NN, Fatobene G, Malki MMA, Ballen KK, Bashey A, Bejanyan N, Meade JB, Rocha V. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy [Internet]. Blood advances. 2019 ; 3( 19): 2836-2844.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1182/bloodadvances.2019000627